FDA approves Darzalex Faspro for treating multiple myeloma

The U.S. Food and Drug Administration has approved Johnson & Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (MM) who are eligible for an autologous stem cell transplant (ASCT).